The broader category covering medicinal drugs also recorded a historic drop. Prices fell 2.7% over the same period, marking the largest year-over-year decline ever recorded for that category.
The numbers immediately became a talking point for the Trump White House, which has made lowering healthcare and prescription costs a major component of its America First economic agenda.
The administration has pointed to several initiatives, including new agreements with pharmaceutical manufacturers and the rollout of TrumpRx, as evidence that its efforts are beginning to produce tangible savings for American consumers.
“No president in modern history has been able to drastically reduce prescription drug prices across the board except for President Trump,” White House spokesman Kush Desai said in an email. “This is a direct result of the President’s willingness to push the envelope with bold policies that actually put Americans and America First.”
One of the administration’s most visible targets has been the rapidly expanding market for GLP-1 medications, including popular drugs used for weight loss and diabetes treatment.
Those medications have frequently carried monthly prices exceeding $1,000 when obtained through insurance and other channels.
TrumpRx, which was launched earlier this year, has sought to offer consumers significantly cheaper access to certain medications. Some GLP-1 treatments are being offered for starting doses as low as $150.
The administration has also pursued direct arrangements with major pharmaceutical companies.
In July, Novo Nordisk and Eli Lilly agreed to provide the federal government with certain medications at a price of $245 per month under a separate Medicare pilot program. The drugs involved include Wegovy, Zepbound and Foundayo.
The agreements followed negotiations that began under Trump last year. Broad details of the deals were announced in November, with the administration subsequently moving to put the discounts into operation.
“In a matter of months, we got up and running these discounts in a way that they were meaningful for American patients,” a White House official said.
The official spoke anonymously because administration staff were not authorized to publicly discuss the matter.
The dramatic July figures did not come out of nowhere. Prescription drug prices have been moving lower for months, suggesting that multiple forces may be contributing to the decline.
Renaissance Macro reported that prescription prices have fallen at a seasonally adjusted annual rate of 6.6% during the past six months, describing the movement as “the sharpest six month drop on record.”
The investment research firm responded to the latest data with a blunt message on X.
“Just what the doctor ordered!” Renaissance Macro posted Wednesday.
But the political battle over who deserves credit for the decline is already underway.
Not every healthcare economist believes Trump’s initiatives are primarily responsible for the dramatic numbers.
Some experts point instead to Medicare negotiations established under former President Joe Biden’s Inflation Reduction Act. The first negotiated prices under that legislation took effect at the beginning of 2026 and currently apply to 10 commonly used prescription drugs.
Richard Frank, a senior fellow at the Brookings Institution and professor emeritus of health economics at Harvard University, argued that the Biden-era law could be playing a larger role than Trump’s newly launched initiatives.
“If I was a betting guy on what mattered most, it would be probably stuff around the Inflation Reduction Act,” Frank said, adding that Trump’s efforts “wouldn’t be where I’d place my money.”
Vanderbilt University health policy professor Stacie Dusetzina made a similar argument, noting that Medicare’s negotiated medications are widely used and therefore more likely to influence the government’s prescription drug price measurements.
She said those drugs “and their prices would likely be reflected in the prescription drug index,” while TrumpRx currently covers “a limited number of branded drugs,” and “aside from GLP1s, they may not be high enough volume to be included.”
The Trump administration, however, rejects the suggestion that the Biden administration’s law should receive most of the credit.
White House officials emphasize that the Inflation Reduction Act took years to produce its first negotiated prices, while Trump has pursued agreements and consumer discounts at a much faster pace.
There is also another factor that could be pushing prices lower: generic drugs.
When major brand-name medications lose patent protection, cheaper generic versions can enter the market. Over time, the Bureau of Labor Statistics can replace older brand-name products in its pricing sample with lower-cost generic alternatives.
That transition can exert significant downward pressure on the prescription drug index.
A number of major medications have lost exclusivity during the past year, potentially adding another source of downward momentum.
And the federal index does not simply measure the advertised sticker price of a drug.
Instead, it reflects what pharmacies actually receive, including payments involving consumers, insurers and Medicare Part D. Consequently, a decline in the index can result from several different developments — including increased generic competition, stronger negotiations or reduced out-of-pocket expenses.
Still, the headline number is difficult to overlook.
Prescription drug prices fell at a pace in July that Americans have not seen since the early 1960s. Whether the Trump administration’s policies, Medicare negotiations, generic competition or a combination of all three deserve the most credit remains a matter of fierce debate.
For the White House, however, the political opportunity is clear.
Trump campaigned heavily on lowering costs for ordinary Americans, and falling prices at the pharmacy counter provide his administration with one of its strongest pieces of economic evidence yet.
The coming months will show whether the historic decline becomes a lasting trend — or merely another chapter in a complicated battle over who can deliver cheaper medicine to American families.
